Jonathan Wygant's most recent trade in Veracyte Inc was a trade of 1,325 Common Stock done at an average price of $46.2 . Disclosure was reported to the exchange on Dec. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.16 per share. | 02 Dec 2025 | 1,325 | 37,420 (0%) | 0% | 46.2 | 61,162 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 40.21 per share. | 07 Nov 2025 | 5,818 | 43,847 (0%) | 0% | 40.2 | 233,929 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 42.33 per share. | 07 Nov 2025 | 5,102 | 38,745 (0%) | 0% | 42.3 | 215,978 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2025 | 2,886 | 49,665 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.11 per share. | 02 Sep 2025 | 1,648 | 46,779 (0%) | 0% | 30.1 | 49,621 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 02 Jun 2025 | 1,848 | 47,915 (0%) | 0% | 26.7 | 49,416 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 13,288 | 49,763 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 02 Mar 2025 | 4,301 | 36,475 (0%) | 0% | 34.8 | 149,503 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.12 per share. | 02 Dec 2024 | 1,087 | 41,226 (0%) | 0% | 44.1 | 47,958 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 43.36 per share. | 02 Dec 2024 | 956 | 40,270 (0%) | 0% | 43.4 | 41,452 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 42.89 per share. | 27 Nov 2024 | 5,032 | 42,313 (0%) | 0% | 42.9 | 215,834 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.55 per share. | 02 Sep 2024 | 1,087 | 47,345 (0%) | 0% | 31.6 | 34,295 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.75 per share. | 02 Jun 2024 | 1,087 | 47,971 (0%) | 0% | 20.7 | 22,555 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 23,942 | 49,058 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.00 per share. | 02 Mar 2024 | 2,337 | 25,116 (0%) | 0% | 24 | 56,088 | Common Stock |
| Veracyte Inc | Wygant Jonathan | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.54 per share. | 02 Dec 2023 | 507 | 27,020 (0%) | 0% | 26.5 | 13,456 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.72 per share. | 02 Jun 2023 | 260 | 28,354 (0%) | 0% | 26.7 | 6,947 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 14,213 | 14,213 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 8,868 | 28,614 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 02 Mar 2023 | 1,224 | 19,746 (0%) | 0% | 24.1 | 29,498 | Common Stock |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 14,598 | 14,598 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Jonathan Wygant | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 8,561 | 20,561 (0%) | 0% | 0 | Common Stock |